4538 Fuso Pharmaceutical Industries,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4538

TSE Prime

Fuso Pharmaceutical Industries,Ltd.

2,541

JPY

-26

(-1.01%)

Dec 23, 3:30 pm JST

16.22

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2021	49,251	2,351	2,227	1,607	183.2	60	May 12, 2021	J-GAAP
Mar, 2022	49,632	1,924	1,996	1,483	169.1	60	May 11, 2022	J-GAAP
Mar, 2023	51,015	2,206	2,215	1,605	183.1	70	May 10, 2023	J-GAAP
Mar, 2024	55,407	1,964	1,868	1,377	160.0	70	May 10, 2024	J-GAAP
Mar, 2025 Guidance	60,000	4,000	3,700	2,600	304.4	82	Nov 11, 2024	J-GAAP
YoY	+8.3%	+103.7%	+98.1%	+88.8%	+90.2%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2020	May 10, 2019	46,200	650	600	400	60	J-GAAP
	May 7, 2020	46,900	1,000	1,060	700	60	J-GAAP
Results	May 12, 2020	46,902	1,010	1,066	707	60	J-GAAP
Mar, 2021	May 12, 2020	Available in future release
	Nov 10, 2020
Results	May 12, 2021
Mar, 2022	May 12, 2021
	Nov 11, 2021
Results	May 11, 2022
Mar, 2023	May 11, 2022
	Nov 9, 2022
	Feb 10, 2023
Results	May 10, 2023
Mar, 2024	May 10, 2023
Results	May 10, 2024
Mar, 2025	May 10, 2024	57,000	2,600	2,300	1,700	80	J-GAAP
	Nov 11, 2024	60,000	4,000	3,700	2,600	82	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2000	45,237	+0.4	Available in future release
Mar, 2001	45,323	+0.2
Mar, 2002	44,226	-2.4
Mar, 2003	41,926	-5.2
Mar, 2004	41,352	-1.4
Mar, 2005	41,919	+1.4
Mar, 2006	42,664	+1.8
Mar, 2007	43,167	+1.2
Mar, 2008	43,991	+1.9
Mar, 2009	45,901	+4.3
Mar, 2010	46,560	+1.4
Mar, 2011	47,469	+2.0
Mar, 2012	44,358	-6.6
Mar, 2013	48,612	+9.6
Mar, 2014	49,098	+1.0
Mar, 2015	47,042	-4.2
Mar, 2016	45,752	-2.7
Mar, 2017	46,782	+2.3
Mar, 2018	45,900	-1.9
Mar, 2019	46,074	+0.4
Mar, 2020	46,902	+1.8
Mar, 2021	49,251	+5.0
Mar, 2022	49,632	+0.8
Mar, 2023	51,015	+2.8
Mar, 2024	55,407	+8.6
Mar, 2025 Guidance	60,000	+8.3	4,000	+103.7	3,700	+98.1	304.4	+90.2

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2023	51,015	2,206	4.32	4.57	2.26	0.72	183.1
Mar, 2024	55,407	1,964	3.54	3.81	1.86	0.75	160.0
Mar, 2025 Guidance	60,000	4,000	6.67	6.86	3.42	0.79	304.4

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	55,407	4,709	4,524	4,871	538.1
Fiscal Year	Mar, 2024	Mar, 1989	Mar, 1990	Mar, 2013	Mar, 2013

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2021	24,666	671	643	440	50.2	30	May 11, 2022	J-GAAP
Oct - Mar, 2022	25,644	921	816	587	67.0	40	May 10, 2023	J-GAAP
Oct - Mar, 2023	27,983	865	770	660	76.7	35	May 10, 2024	J-GAAP
Oct - Mar, 2024 Guidance	30,261	1,566	1,557	1,065	124.7	42	Nov 11, 2024	J-GAAP
YoY	+8.1%	+81.0%	+102.2%	+61.4%	+62.6%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2022	1,924	1,945	3,498	-1,553	-1,671	7,347	10.60	J-GAAP
Mar, 2023	2,206	1,480	2,853	-1,373	-813	8,014	11.06	J-GAAP
Mar, 2024	1,964	-2,909	627	-3,536	14	5,120	6.75	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	25,371	1,285	1,399	1,018	116.1	63.2	Nov 9, 2022	J-GAAP
Apr - Sep, 2023	27,424	1,099	1,098	717	82.2	58.8	Nov 10, 2023	J-GAAP
Apr - Sep, 2024	29,739	2,434	2,143	1,535	179.8	57.9	Nov 11, 2024	J-GAAP
YoY	+8.4%	+121.5%	+95.2%	+114.1%	+118.7%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2022	13,848	680	661	475	54.2	4.9	Feb 10, 2023	J-GAAP
Jan - Mar, 2023	11,796	241	155	112	12.8	2.0	May 10, 2023	J-GAAP
Apr - Jun, 2023	13,507	589	658	479	54.7	4.4	Aug 9, 2023	J-GAAP
Jul - Sep, 2023	13,917	510	440	238	27.3	3.7	Nov 10, 2023	J-GAAP
Oct - Dec, 2023	15,406	744	731	510	59.0	4.8	Feb 13, 2024	J-GAAP
Jan - Mar, 2024	12,577	121	39	150	17.4	1.0	May 10, 2024	J-GAAP
Apr - Jun, 2024	14,622	1,150	909	632	74.1	7.9	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	15,117	1,284	1,234	903	105.7	8.5	Nov 11, 2024	J-GAAP
YoY	+8.6%	+151.8%	+180.5%	+279.4%	+287.6%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct - Dec, 2019	12,556	-0.9	Available in future release
Jan - Mar, 2020	10,673	+2.1
Apr - Jun, 2020	12,430	+5.8
Jul - Sep, 2020	12,500	+4.8
Oct - Dec, 2020	13,282	+5.8
Jan - Mar, 2021	11,039	+3.4
Apr - Jun, 2021	12,599	+1.4
Jul - Sep, 2021	12,367	-1.1
Oct - Dec, 2021	13,305	+0.2
Jan - Mar, 2022	11,361	+2.9
Apr - Jun, 2022	12,367	-1.8
Jul - Sep, 2022	13,004	+5.2
Oct - Dec, 2022	13,848	+4.1
Jan - Mar, 2023	11,796	+3.8
Apr - Jun, 2023	13,507	+9.2
Jul - Sep, 2023	13,917	+7.0
Oct - Dec, 2023	15,406	+11.3
Jan - Mar, 2024	12,577	+6.6
Apr - Jun, 2024	14,622	+8.3
Jul - Sep, 2024	15,117	+8.6	1,284	+151.8	1,234	+180.5	105.7	+287.2

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	15,406	1,284	1,234	3,184	351.7
Fiscal Year	Dec, 2023	Sep, 2024	Sep, 2024	Dec, 2012	Dec, 2012

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2022	3,936.70	49.8	69,334	34,532	14,731	0.34	May 11, 2022	J-GAAP
Mar, 2023	4,064.76	49.2	72,466	35,649	15,811	0.32	May 10, 2023	J-GAAP
Mar, 2024	4,290.55	48.4	75,802	36,661	16,541	0.35	May 10, 2024	J-GAAP
Apr - Sep, 2024	ー	49.9	75,999	37,899	17,778	0.36	Nov 11, 2024	J-GAAP

Fuso Pharmaceutical Industries,Ltd.(4538) Financial Results